Project Acronym:
IBD-Character

Project Reference:
305676

Duration: 52 months

Contract Type:
Small or medium-scale
focused research project

Project Funding:
6 million euros

Research area:
HEALTH.2012.2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joint and/or digestive system

This project has received funding from the European Union's Seventh Framework Program for research, technological development and demonstration under grant agreement #305676

Society

The annual aggregate cost of IBD for society exceeds 25 billion Euros in Europe alone

Inflammatory bowel diseases are characterized by severe chronic intestinal inflammation with huge impact on quality of life. Current treatment is expensive and lacks in therapeutic precision, which reduces efficacy and safety and the disease progress throughout life. Delaying the onset of the disease as well as finding novel potential targets for intervention strategies would dramatically increase the likelihood of healthy, active and independent lives until old age. The incidence of IBD is high and escalating; as a result, the annual aggregate cost of IBD, including direct (medical) and indirect (productivity) loss, exceeds 25 billion Euros in Europe alone, reflecting the strategic importance for society at large, both from patient and health care perspectives. 

More information about IBD can be found on:

www.ibdbiom.eu (A project funded under FP7)

www.efcca.org (European Federation of Crohn's & Ulcerative Colitis Association)